Liquid Hallmark tests are a non-invasive blood-based cancer diagnostic that detects multiple cancer-causing mutations and viruses in circulating tumor DNA at the same time. The test targets 50 genes, including fusions and microsatellite instability (MSI). It is extremely effective because it detects damaged DNA, which is the starting point for cancer, and has a sensitivity accuracy of 95%. The test can pinpoint the exact location of the lesion, assisting in the early detection of cancer.
Furthermore, the test can pinpoint the origin of the cancer as well as target 14 different types of cancer, including breast, colon, liver, lung, bile duct, and nasopharyngeal cancers. It also includes viruses associated with cancer, such as the Epstein-Barr virus (EBV) and the Hepatitis B virus (HBV). Aids in the matching of genomic alterations to targeted therapy and immunotherapy, as well as monitoring treatment response. Individual results are tailored to each patient based on their test profile. As a result, this test is appropriate for those who are at risk or want to eliminate risk at an early stage.